Morgan Stanley raised the firm’s price target on Moderna (MRNA) to $39 from $38 and keeps an Equal Weight rating on the shares. The company’s Q4 was “mainly uneventful” given the January preannouncement, the analyst tells investors in a research note. The firm says the enterprise value of the stock appears to be pricing in $2B-B$2.5B in revenue, and “could be settling into a support level.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s Market Position and Future Prospects: Hold Rating Reflects Cautious Stance Amid Execution Challenges and Financial Strategies
- Moderna’s Earnings Call: A Year of Challenges and Strategic Growth
- Moderna Reports 2024 Loss, Eyes Future Growth
- Moderna’s Financial Uncertainty and Strategic Risks Drive Sell Rating by Alexandria Hammond
- Moderna price target lowered to $25 from $35 at Wolfe Research